FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308365786> ?p ?o ?g. }

• W4308365786 endingPage "95" @default.
• W4308365786 startingPage "87" @default.
• W4308365786 abstract "Purpose Black men in the United States experience significantly higher incidence of and mortality from prostate cancer (PCa) than non-Black men. The cause of this disparity is multifactorial, though inequitable access to curative radiation modalities, including low-dose-rate (LDR) brachytherapy, may contribute. Despite this, there are few analyses evaluating the potential of different radiation therapies to mitigate outcome disparities. Therefore, we examined the clinical outcomes of Black and non-Black patients treated with definitive LDR brachytherapy for PCa. Methods Data were collected for all patients treated with definitive LDR brachytherapy between 2005 and 2018 on a retrospective institutional review board approved protocol. Pearson χ2 analysis was used to assess demographic and cancer differences between Black and non-Black cohorts. Freedom from biochemical failure (FFBF) was calculated using Kaplan-Meier analysis. Univariate and multivariate analyses were used to identify factors predictive of biochemical failure. Results One hundred and sixty-seven patients were included in the analysis (Black: n = 81; 48.5%) with a median follow-up of 88.4 months. Black patients were from lower income communities (P < .01), had greater social vulnerability (P < .01), and had a longer interval between diagnosis and treatment (P = .011). Overall cumulative FFBF was 92.3% (95% confidence interval [CI], 87.8%-96.8%) at 5 years and 87.7% (95% CI, 82.0%-93.4%) at 7 years. There was no significant difference in FFBF in Black and non-Black patients (P = .114) and Black race was not independently predictive of failure (hazard ratio, 1.51; 95% CI, 0.56-4.01; P = .42). Overall survival was comparable between racial groups (P = .972). Only nadir prostate-specific antigen was significantly associated with biochemical failure on multivariate (hazard ratio, 3.57; 95% CI, 02.44-5.22; P < .001). Conclusions Black men treated with LDR brachytherapy achieved similar FFBF to their non-Black counterparts despite poorer socioeconomic status. This suggests that PCa treatment with brachytherapy may eliminate some disparities in clinical outcomes. Black men in the United States experience significantly higher incidence of and mortality from prostate cancer (PCa) than non-Black men. The cause of this disparity is multifactorial, though inequitable access to curative radiation modalities, including low-dose-rate (LDR) brachytherapy, may contribute. Despite this, there are few analyses evaluating the potential of different radiation therapies to mitigate outcome disparities. Therefore, we examined the clinical outcomes of Black and non-Black patients treated with definitive LDR brachytherapy for PCa. Data were collected for all patients treated with definitive LDR brachytherapy between 2005 and 2018 on a retrospective institutional review board approved protocol. Pearson χ2 analysis was used to assess demographic and cancer differences between Black and non-Black cohorts. Freedom from biochemical failure (FFBF) was calculated using Kaplan-Meier analysis. Univariate and multivariate analyses were used to identify factors predictive of biochemical failure. One hundred and sixty-seven patients were included in the analysis (Black: n = 81; 48.5%) with a median follow-up of 88.4 months. Black patients were from lower income communities (P < .01), had greater social vulnerability (P < .01), and had a longer interval between diagnosis and treatment (P = .011). Overall cumulative FFBF was 92.3% (95% confidence interval [CI], 87.8%-96.8%) at 5 years and 87.7% (95% CI, 82.0%-93.4%) at 7 years. There was no significant difference in FFBF in Black and non-Black patients (P = .114) and Black race was not independently predictive of failure (hazard ratio, 1.51; 95% CI, 0.56-4.01; P = .42). Overall survival was comparable between racial groups (P = .972). Only nadir prostate-specific antigen was significantly associated with biochemical failure on multivariate (hazard ratio, 3.57; 95% CI, 02.44-5.22; P < .001). Black men treated with LDR brachytherapy achieved similar FFBF to their non-Black counterparts despite poorer socioeconomic status. This suggests that PCa treatment with brachytherapy may eliminate some disparities in clinical outcomes." @default.
• W4308365786 created "2022-11-11" @default.
• W4308365786 creator A5004217393 @default.
• W4308365786 creator A5021553632 @default.
• W4308365786 creator A5024829093 @default.
• W4308365786 creator A5045014025 @default.
• W4308365786 creator A5047183090 @default.
• W4308365786 creator A5052573263 @default.
• W4308365786 creator A5054458398 @default.
• W4308365786 creator A5064199648 @default.
• W4308365786 creator A5069008967 @default.
• W4308365786 creator A5075165181 @default.
• W4308365786 creator A5086520901 @default.
• W4308365786 date "2023-05-01" @default.
• W4308365786 modified "2023-10-14" @default.
• W4308365786 title "Racial Analysis of Clinical and Biochemical Outcomes in Patients With Prostate Cancer Treated With Low-Dose-Rate Brachytherapy" @default.
• W4308365786 cites W1967229770 @default.
• W4308365786 cites W1979665150 @default.
• W4308365786 cites W1986742341 @default.
• W4308365786 cites W1993657718 @default.
• W4308365786 cites W2004546289 @default.
• W4308365786 cites W2021425787 @default.
• W4308365786 cites W2045398464 @default.
• W4308365786 cites W2047281197 @default.
• W4308365786 cites W2062435906 @default.
• W4308365786 cites W2072905710 @default.
• W4308365786 cites W2078409539 @default.
• W4308365786 cites W2101001966 @default.
• W4308365786 cites W2120455310 @default.
• W4308365786 cites W2306059002 @default.
• W4308365786 cites W2308286538 @default.
• W4308365786 cites W2443061927 @default.
• W4308365786 cites W2524479840 @default.
• W4308365786 cites W2609553042 @default.
• W4308365786 cites W2783008652 @default.
• W4308365786 cites W2794628520 @default.
• W4308365786 cites W2905488855 @default.
• W4308365786 cites W2944891078 @default.
• W4308365786 cites W2980223381 @default.
• W4308365786 cites W3001534873 @default.
• W4308365786 cites W3014014551 @default.
• W4308365786 cites W3020571969 @default.
• W4308365786 cites W3083793943 @default.
• W4308365786 cites W3092607855 @default.
• W4308365786 cites W3119005666 @default.
• W4308365786 cites W3127066344 @default.
• W4308365786 cites W3176357168 @default.
• W4308365786 cites W4206446824 @default.
• W4308365786 doi "https://doi.org/10.1016/j.ijrobp.2022.10.027" @default.
• W4308365786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36336224" @default.
• W4308365786 hasPublicationYear "2023" @default.
• W4308365786 type Work @default.
• W4308365786 citedByCount "0" @default.
• W4308365786 crossrefType "journal-article" @default.
• W4308365786 hasAuthorship W4308365786A5004217393 @default.
• W4308365786 hasAuthorship W4308365786A5021553632 @default.
• W4308365786 hasAuthorship W4308365786A5024829093 @default.
• W4308365786 hasAuthorship W4308365786A5045014025 @default.
• W4308365786 hasAuthorship W4308365786A5047183090 @default.
• W4308365786 hasAuthorship W4308365786A5052573263 @default.
• W4308365786 hasAuthorship W4308365786A5054458398 @default.
• W4308365786 hasAuthorship W4308365786A5064199648 @default.
• W4308365786 hasAuthorship W4308365786A5069008967 @default.
• W4308365786 hasAuthorship W4308365786A5075165181 @default.
• W4308365786 hasAuthorship W4308365786A5086520901 @default.
• W4308365786 hasConcept C121608353 @default.
• W4308365786 hasConcept C126322002 @default.
• W4308365786 hasConcept C144301174 @default.
• W4308365786 hasConcept C207103383 @default.
• W4308365786 hasConcept C2777416452 @default.
• W4308365786 hasConcept C2780192828 @default.
• W4308365786 hasConcept C38180746 @default.
• W4308365786 hasConcept C44249647 @default.
• W4308365786 hasConcept C509974204 @default.
• W4308365786 hasConcept C71924100 @default.
• W4308365786 hasConceptScore W4308365786C121608353 @default.
• W4308365786 hasConceptScore W4308365786C126322002 @default.
• W4308365786 hasConceptScore W4308365786C144301174 @default.
• W4308365786 hasConceptScore W4308365786C207103383 @default.
• W4308365786 hasConceptScore W4308365786C2777416452 @default.
• W4308365786 hasConceptScore W4308365786C2780192828 @default.
• W4308365786 hasConceptScore W4308365786C38180746 @default.
• W4308365786 hasConceptScore W4308365786C44249647 @default.
• W4308365786 hasConceptScore W4308365786C509974204 @default.
• W4308365786 hasConceptScore W4308365786C71924100 @default.
• W4308365786 hasIssue "1" @default.
• W4308365786 hasLocation W43083657861 @default.
• W4308365786 hasLocation W43083657862 @default.
• W4308365786 hasOpenAccess W4308365786 @default.
• W4308365786 hasPrimaryLocation W43083657861 @default.
• W4308365786 hasRelatedWork W2138863125 @default.
• W4308365786 hasRelatedWork W2338961863 @default.
• W4308365786 hasRelatedWork W2529939135 @default.
• W4308365786 hasRelatedWork W2597301728 @default.
• W4308365786 hasRelatedWork W274490372 @default.
• W4308365786 hasRelatedWork W2770409748 @default.
• W4308365786 hasRelatedWork W2979210130 @default.
• W4308365786 hasRelatedWork W2981944047 @default.

• next